PDCD1 and hepatocellular carcinoma: In this study, we conducted a head-to-head comparison to determine the efficacy and safety of anti-PD-1-based immunotherapies in a real-world cohort of patients with unresectable HCC and tried to provide suggestions to clinicians to select optimal inhibitors for patients.